Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
In line with its continuous efforts to improve internal stem cell procedures, Cryo-Save proudly announces the appointment of the highly knowledgeable stem cell expert Dr. Marcin Jurga. read more
TiGenix (NYSE Euronext: TIG) announced today that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands. read more
QUINVITA, the Industrial Crop Technology Company today announced the closure of its capital round, raising EUR 1.5 million from a group of investors including Think2Act Arkiv, Group Vanden Avenne Izegem and a number of private investors. read more
"The ease at which Thrombogenics recently raised € 78m has put Belgian biotech at the European top at the start of 2012", Jan De Kerpel, KBC Securities read more
Galapagos NV (Euronext: GLPG) gave an R&D update, indicating progress and plans for its large portfolio of more than 50 research programs. In addition to laying out the competitive positioning and Phase II plans for selective JAK1 inhibitor GLPG0634 in rheumatoid arthritis, a number of other topics were discussed, including read more
TiGenix NV (NYSE Euronext Brussels: TIG) announces that it has completed the third and final phase of the Orthomimetics acquisition. read more
Earlier this year Rudy Dekeyser announced his departure from VIB, to accept a new challenge in the venture capital world. Since the start of VIB in July 1995, VIB has been led by the tandem Jo Bury and Rudy Dekeyser. From June 1st onwards Johan Cardoen will succeed Rudy Dekeyser as managing director and director tech transfer of VIB. read more
genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole. read more
